TNF-alpha inhibitors

Neonatal medical care

id	Study   Auto Chaparro, 2018Lichtenstein - infliximab, 2018Seirafi, 2014	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S3066 R4668	Chaparro, 2018	Intensive care unit admission	3 months (or more) before pregnancy or during pregnancy excluded	retrospective cohort	unexposed, sick	Adjustment: No	2.35 [1.21;4.54] C excluded (exposition period)	27/388   14/453	41	388		ref
S4103 R8790	Lichtenstein - infliximab, 2018	Infants prolonged hospitalization	3 months (or more) before pregnancy or during pregnancy excluded	prospective cohort	exposed to other treatment, sick	Adjustment: No	0.38 [0.13;1.14] C excluded (exposition period)	5/81   12/82	17	81		ref
S3037 R4573	Seirafi, 2014	Respiratory distress syndrome	3 months (or more) before pregnancy or during pregnancy excluded	retrospective cohort	unexposed, sick	Adjustment: No before conception and/or during pregnancy	1.28 [0.30;5.52] C excluded (exposition period)	5/118   3/90	8	118		ref
					Total	0 studies	NaN [NaN;NaN]		0	0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis